Neuren Pharmaceuticals (OTCMKTS:NURPF) Stock Price Down 5.5% – What’s Next?

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) shares traded down 5.5% during mid-day trading on Tuesday . The company traded as low as C$12.20 and last traded at C$12.20. 100 shares were traded during mid-day trading, an increase of 0% from the average session volume of 100 shares. The stock had previously closed at C$12.91.

Neuren Pharmaceuticals Stock Down 5.5%

The company’s 50 day simple moving average is C$12.66 and its 200 day simple moving average is C$12.35.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.